SCHEMBL772292

SCHEMBL772292

O=C(NCCCC(=O)N1CCCC2CCCCC21)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 11/20 0.70
HSD11B1 P28845 2/20 0.53
HSD17B1 P14061 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.50
PREP P48147 2/20 0.50
RAB9A P51151 2/20 0.50
FAP Q12884 1/20 0.50
NPC1 O15118 1/20 0.50
DPP7 Q9UHL4 1/20 0.48
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
ACE P12821 1/20 0.46
ACE2 Q9BYF1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770799 0.93 DPP4 (0.60) DPP4HSD11B1HSD17B1SMN1; SMN2PREP
SCHEMBL769889 0.84 HSD11B1 (0.57) DPP4HSD11B1SMN1; SMN2RAB9ANPC1
SCHEMBL771343 0.83 DPP4 (0.49) DPP4HSD11B1SMN1; SMN2RAB9ANPC1
SCHEMBL771667 0.82 PREP (0.55) DPP4PREPFAP
SCHEMBL771992 0.82 MEN1 (0.55) DPP4HSD11B1PREPRAB9ANPC1
SCHEMBL772462 0.82 ALDH1A1 (0.53) DPP4SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL771007 0.82 NPC1 (0.54) DPP4SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL772219 0.81 DPP4 (0.47) DPP4HSD11B1SMN1; SMN2RAB9ANPC1
SCHEMBL771552 0.81 KMT2A (0.54) DPP4SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL771550 0.81 KMT2A (0.54) DPP4SMN1; SMN2RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DPP4 1092/4885HSD11B1 1/4885HSD17B1 2/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DPP4 1125/4885HSD11B1 1/4885HSD17B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.